CD8+ CTL clones recognizing unique minor histocompatibility antigens
| Patient | HLA | Sample day * | Therapy † | CTL clone ‡ | Class I MHC restriction | % specific lysis § | RCC reactive | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | B | C | Patient | Donor | |||||||||
| 2 | 2, 25 | 8, 51 | w7, w14 | 196 | None | 5C10(+) ¶ | HLA-B51 | 68 | 0 | + | |||
| 2B3(+) | HLA-A2 | 63 | -4 | + | |||||||||
| 420 | IFN-α | Clone 9 | HLA-A2 | 86 | 2 | + | |||||||
| Clone 17 | HLA-A2 | 63 | 3 | + | |||||||||
| 3 | 3, 24 | 7, 40 | w4, w7 | 61 ∥ | CSP | 3A12 | HLA-B7 | 50 | 1 | + | |||
| 5E1 | ND | 48 | 1 | ND | |||||||||
| 2H4 | HLA-A3 | 86 | 0 | − | |||||||||
| 12D10(+) | ND | 66 | -1 | ND | |||||||||
| 4 | 11, 24 | 54, 67 | w1, w7 | 91 | CSP | 23G11(+) | HLA-B54 | 78 | 2 | ND | |||
| Pred | 24B4–4 | HLA-A11 | 28 | 2 | − | ||||||||
| 5 | 26, 32 | 7, 38 | w7, w12 | 105 | CSP | 13A3 | HLA-B7 | 78 | 0 | ND | |||
| Pred | 13H9(+) | ND | 82 | 1 | ND | ||||||||
| 6 | 1, 2 | 8, 15 | w4, w7 | 35 | CSP | 1D8 | HLA-A2 | 82 | 3 | + | |||
| 12B3(+) | HLA-A2 | 69 | 4 | + | |||||||||
| 24B4–6 | ND | 64 | 4 | ND | |||||||||
| 58 | None | None | |||||||||||
* Posttransplant day peripheral blood was collected as a source for in vitro T-cell culture.
† Immune-modifying therapies administered at the time peripheral blood samples were obtained: CSP, cyclosporine; Pred, prednisone.
‡ CTL clones were confirmed to be of donor origin by analysis with fluorescence in situ hybridization with Y chromosome-specific probes in sex-mismatched donor/recipient pairs or informative microsatellite markers in sex-matched donor-recipient pairs.
§ Representative specific lysis of patient- and donor-derived EBV-LCL targets in a 4-hour chromium-release cytotoxicity assay with an E:T ratio of 10:1 or 5:1.
¶ Isolation of additional clone(s) with the same specificity for allogeneic targets indicated by (+).
∥ Posttransplant day relative to patient’s second transplant.
Abbreviation: ND, not determined.